
|Videos|June 9, 2020
SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?
Author(s)Grant M. Gallagher
Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Advertisement
Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Measles Update: February 6, 2026
2
Pritelivir Improves Outcomes in Immunocompromised Patients With Refractory Herpes Simplex Virus
3
HIV in the Black Community: Shifting from Stigma and Health Inequalities to Communication and Care Initiatives
4
Antibiotics Deconstructed: IV Fosfomycin
5

































































































































